Division of Pediatric Hematology Oncology. University of Alabama at Birmingham, Birmingham, Alabama.
Division of Pediatric Hematology Oncology. University of Alabama at Birmingham, Birmingham, Alabama
Pediatrics. 2018 Jul;142(1). doi: 10.1542/peds.2017-3804. Epub 2018 Jun 11.
Incidental isolated mild to moderate thrombocytopenia is a frequent laboratory finding prompting a referral to pediatric hematology-oncology. We tested the hypothesis that patients with isolated asymptomatic mild thrombocytopenia would not progress to require an intervention from a pediatric hematologist-oncologist.
This is a 5-year retrospective review of 113 patients referred to pediatric hematology-oncology for isolated thrombocytopenia. Initial, lowest, and current platelet counts along with clinical course and need for interventions were recorded. Thrombocytopenia was categorized as mild (platelet count: 101-140 × 10/μL), moderate (platelet count: 51-100 × 10/μL), severe (platelet count: 21-50 × 10/μL), and very severe (platelet count: ≤20 × 10/μL).
Eight of 48 patients (17%) referred for initial mild isolated thrombocytopenia progressed to moderate thrombocytopenia at 1 visit. At present, 2 of these patients have moderate thrombocytopenia, 17 remain with mild thrombocytopenia, and 29 patients have resolved thrombocytopenia. Nine of 65 patients (14%) referred for moderate thrombocytopenia progressed to severe or very severe thrombocytopenia on 1 occasion. At present, no patients have severe thrombocytopenia, 18 remain with moderate thrombocytopenia, 14 improved to mild thrombocytopenia, and 33 have resolved thrombocytopenia. Only 3 patients required interventions from a hematologist, whereas 10 patients required therapy from other subspecialties.
We only identified 3 patients (3%) with mild to moderate thrombocytopenia who required an intervention from a hematologist to improve platelet counts. Patients with isolated mild thrombocytopenia with a normal bleeding history and physical examination findings frequently have normalized their platelet counts within 1 month.
偶然发现的轻度至中度孤立性血小板减少症是一种常见的实验室发现,会促使患者转至儿科血液肿瘤科就诊。我们检验了这样一种假说,即患有孤立性无症状轻度血小板减少症的患者不会进展至需要儿科血液肿瘤学家进行干预的程度。
这是一项对 113 例因孤立性血小板减少症转至儿科血液肿瘤科的患者进行的 5 年回顾性研究。记录了初始、最低和当前血小板计数以及临床过程和干预需求。血小板减少症分为轻度(血小板计数:101-140×10/μL)、中度(血小板计数:51-100×10/μL)、重度(血小板计数:21-50×10/μL)和极重度(血小板计数:≤20×10/μL)。
48 例初始轻度孤立性血小板减少症患者中有 8 例(17%)在 1 次就诊时进展为中度血小板减少症。目前,这 2 例患者为中度血小板减少症,17 例仍为轻度血小板减少症,29 例患者血小板减少症已缓解。65 例中度血小板减少症患者中有 9 例(14%)在 1 次就诊时进展为重度或极重度血小板减少症。目前,无患者为重度血小板减少症,18 例仍为中度血小板减少症,14 例改善为轻度血小板减少症,33 例血小板减少症已缓解。仅 3 例患者需要血液科医生干预,而 10 例患者需要其他专科医生治疗。
我们仅发现 3 例(3%)轻度至中度血小板减少症患者需要血液科医生干预以提高血小板计数。孤立性轻度血小板减少症且具有正常出血史和体格检查结果的患者,其血小板计数通常在 1 个月内恢复正常。